ReviewBMC neurology2026
Clinical and molecular characterization of Krabbe disease in Iranian patients: case report and literature review.
Review in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Krabbe disease (KD, OMIM #245200) is a rare autosomal recessive lysosomal storage disorder characterized by severe demyelination affecting both the central and peripheral nervous systems. Here we report the clinical and molecular findings of two unrelated Iranian patients with KD, originating from consanguineous families. Genetic analysis was initially performed using whole-exome sequencing (WES), then validated by Sanger sequencing. WES identified a novel homozygous variant in the GALC, c.836T > G (p.L279X), in patient-1. In patient-2, WES detected a previously reported homozygous variant, c.578T > C (p.I193T), in the GALC. Sanger sequencing confirmed homozygosity of these variants in the affected patients and heterozygosity in their parents. The affected brother of patient-2 was also homozygous for the variant c.578T > C. The pathogenicity of the detected variants was supported by various lines of evidence, including in silico predictive tools, segregation analysis, and population genetic databases frequency. Our findings expand the mutational spectrum of GALC and highlight the clinical heterogeneity of KD. Morover, these finding contribute to improved genotype-phenotype correlations, which are essential for accurate diagnosis, prognostic valuation, and genetic counseling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.